Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.

Objective: To evaluate the safety and efficacy of 5% imiquimod cream for cutaneous dysplasia in high-risk renal transplant recipients.

Design: A randomized, blinded, placebo-controlled study comparing treated with control skin.

Setting: A specialist organ transplant dermatology clinic.